What is the market's earnings forecast for GeoVax Labs next quarter?

What is GeoVax Labs's gross profit margin?

Did GeoVax Labs beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for GeoVax Labs year over year?

What were the key takeaways from GeoVax Labs's earnings call?

What factors drove the changes in GeoVax Labs's revenue and profit?

What were the key takeaways from GeoVax Labs’s earnings call?

What does GeoVax Labs do and what are its main business segments?

- **GEO-MVA Milestone**: EMA guidance enables Phase III trial, with clinical manufacturing underway for early 2026 evaluation.
- **CM04S1 Promise**: Phase II data shows potential for immunocompromised patients, aligning with IDSA guidelines.
- **Financial Focus**: $5M cash balance supporting key programs, with exploration of nondilutive funding to extend runway.
- **Strategic Growth**: Increased collaboration interest for MVA supply chain and oncology partnerships.
- **Risk Management**: Net loss up 2% YoY due to clinical costs, but cost control efforts maintained R&D efficiency.

**【CEO Summary Section】**
- **GEO-MVA Progress**: Received EMA guidance to bypass Phase I/II trials, initiating Phase III immuno-bridging trial early 2026. Manufacturing underway for clinical evaluation and potential stakeholder use.
- **CM04S1 Development**: Multi-antigen COVID-19 vaccine shows promise for immunocompromised patients, with Phase II trials ongoing in chronic lymphocytic leukemia (CLL) and hematologic malignancies.
- **Gedeptin Expansion**: Phase II trial evaluating neoadjuvant Gedeptin + pembro in head and neck cancer; exploring combination with other immune checkpoint inhibitors (ICIs).
- **Strategic Partnerships**: Increased interest from industry players and nondilutive funding organizations; focus on U.S. supply chain onshoring for MVA vaccines.
- **Global Engagement**: Active discussions with WHO, Africa CDC, and U.S. government on Mpox/Smallpox vaccine needs and cGMP manufacturing capabilities.

**【CFO Financial Commentary】**
- **Revenue**: $2.5M for 9 months (down 19% YoY) due to termination of BARDA Project NextGen contract.
- **Expenses**: R&D ($15.1M) down 6% YoY; G&A ($4.6M) up 21% YoY due to personnel and investor relations costs.
- **Net Loss**: $17M for 9 months (up 2% YoY) driven by clinical trial and manufacturing costs.
- **Cash Position**: $5M as of Q3, with focus on funding GEO-MVA, CM04S1, and Gedeptin programs.
- **Funding Strategy**: Exploring partnerships, nondilutive funding, and potential equity offerings to extend cash runway.

**【Q&A Highlights】**
- **Emergency Use of MVA**: CEO emphasized need for clinical evaluation before emergency authorization, though WHO discussions suggest potential pathways for rapid deployment.
- **Collaboration Strategy**: Open to regional partnerships (e.g., Southern Hemisphere for Mpox) and CDMO collaborations (e.g., Oxford Biomedica for GEO-MVA manufacturing).
- **Gedeptin Combination Potential**: Interest in testing with other ICIs, though current focus is on pembro combination trial.
- **Stakeholder Interest**: Heightened government and industry focus on U.S.-based MVA supply chains and immunocompromised patient vaccines.


GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

- **GEO-MVA Fast-Track**: EMA approval for Phase III immunobridging trial, targeting H2 2026 start. U.S. government interest in domestic manufacturing.
- **Gedeptin Trial Design**: First-line head and neck cancer trial with 36-40 patients, primary endpoint of pathological response. Enrollment expected late 2026.
- **Financial Stability**: $3.1M cash post-July offering, with focus on partnerships and non-dilutive funding to extend runway.
- **COVID Vaccine Focus**: Multi-antigen approach for immunocompromised, aligning with HHS guidance. investigator-initiated CLL trial nearing completion.

**【CEO Summary Section】**
- **GEO-MVA Progress**: Received EMA guidance for immunobridging trial, bypassing Phase I/II. Clinical batch production complete for late 2025 evaluation. Discussions with U.S. government on domestic manufacturing and stockpiling.
- **GEO-CMO4S1 Update**: Multi-antigen COVID-19 vaccine for immunocompromised patients. Phase II trial enrollment ongoing, with presentations at major conferences. Investigator-initiated CLL trial shows promise.
- **Gedeptin Trial Update**: Phase II head and neck cancer trial targeting first-line therapy. Protocol modified to align with KEYNOTE-689, with primary endpoint of major pathological response. Enrollment expected to begin late 2026.
- **MVA Manufacturing**: Advanced MVA process aims to reduce reliance on non-U.S. suppliers. Discussions with global health agencies for stockpile opportunities.

**【CFO Financial Commentary】**
- **Revenue**: $2.5M (6 months) from BARDA contract, terminated in Q2 with minimal cash impact ($<0.75M annual). 
- **Expenses**: R&D $10M (16% YoY increase), G&A $3.2M (27% YoY increase) due to consulting and stock-based compensation.
- **Cash Position**: $3.1M at June 30, 2025. Follow-on offering in July added $6M, extending cash runway. Focus on strategic partnerships and non-dilutive funding.

**【Q&A Key Highlights】**
- **GEO-MVA Trial Timing**: Phase III immunobridging trial in Europe and Africa set for H2 2026. Data may support U.S. discussions with FDA. Manufacturing not a limiting factor; regulatory approvals and site readiness are key.
- **Gedeptin Design**: Simon 2-stage trial with 36-40 patients targeting pathological response. Secondary endpoint: 1-year event-free survival. Enrollment expected to be rapid in first-line patients.
- **BARDA Manufacturing**: Proposal for AGE1 continuous cell line process under review. Funding dependent on government allocation, with potential 2-year delay.
- **Regulatory Strategy**: Leveraging EMA pathway for expedited approval, with parallel discussions for U.S. emergency use. Focus on unmet needs in immunocompromised populations.


GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

- **Project NextGen Impact**: BARDA termination minimally affects GeoVax ($<750k/year), with trials in immunocompromised patients continuing.
- **CM04S1 Potential**: Targeting 40M+ U.S. adults with weak immune responses; Phase 2 CLL trial nearing completion.
- **Government Manufacturing Push**: BARDA proposal for U.S.-based MVA production approved; key for national vaccine security.
- **Financial Resilience**: $7.4M cash runway supports clinical trials; exploring partnerships to extend funding.


**【CEO Opening Remarks】**
- **Project NextGen Termination**: Received a Stop Work Order from BARDA, resulting in less than $750k annual financial impact. No concerns over vaccine safety or efficacy.
- **CM04S1 Focus**: Phase 2 trials in immunocompromised patients (e.g., CLL) continue, targeting 40+ million U.S. adults with inadequate immune responses.
- **GEO-MVA Progress**: Completed cGMP production for mpox/smallpox vaccine, with clinical trials planned for 2025. Aims to address global MVA supply dependency.
- **Gedeptin Oncology Pipeline**: Phase 2 trial in head and neck cancer underway, with potential for combination therapies.

**【CFO Financial Update】**
- **Q1 2025 Revenue**: $1.6M from BARDA contract (vs. $0 in 2024), offset by termination impact.
- **R&D Expenses**: $5.4M (+21% YoY) driven by BARDA, GEO-MVA, and Gedeptin trials.
- **Net Loss**: $5.4M ($0.45/share) vs. $5.9M ($2.47/share) in 2024.
- **Cash Position**: $7.4M as of March 31, 2025, supporting clinical trials and strategic partnerships.

**【Q&A Key Points】**
- **Vaxart Comparison**: Unlike Vaxart, GeoVax focuses on immunocompromised populations, avoiding large healthy volunteer trials.
- **Government Support**: Advanced MVA manufacturing proposal deemed worthy by BARDA, with potential U.S.-based production.
- **Trial Design**: CM04S1 trials compare multi-antigen vaccine to mRNA in high-risk groups, aligning with HHS preference for multi-antigen vaccines.
- **Manufacturing Risk**: No U.S.-based MVA manufacturers; rely on Oxford Biomedica for current production but pursuing domestic options.


GeoVax Labs (GOVX)-1 May 25-2025 Q1 Earnings call transcript

- **$400M BARDA Deal**: Next-gen COVID vaccine targeting 40M+ immunocompromised adults, with trials set for late 2025.
- **Mpox Vaccine Urgency**: Completed manufacturing for 20M+ doses, with WHO and Africa CDC seeking emergency use authorization.
- **Financial Focus**: $4M in BARDA revenue in 2024, with $23.7M R&D investment to advance pipeline.
- **Key Risk**: Gedeptin trial delayed to mid-2026 due to manufacturing issues.
- **Strategic Advantage**: MVA platform offers durability (8-12 months) vs. mRNA's 3-6 months, with no need for variant reconfiguration.


**【CEO Key Updates】**
- **BARDA Project NextGen Award**: Secured $400M contract for GEO-CM04S1, a next-gen COVID-19 vaccine targeting immunocompromised patients. Clinical trials expected to begin late 2025.
- **GEO-MVA Progress**: Completed cGMP manufacturing for Mpox/Smallpox vaccine, with clinical trials anticipated in H2 2025. 
- **MVA Platform Advantages**: Non-replicating viral vector (MVA) offers superior safety profile, particularly for immunocompromised populations, unlike mRNA vaccines.
- **Global Partnerships**: Engaging with WHO, Africa CDC, and U.S. government to address Mpox vaccine shortages and establish decentralized manufacturing.

**【CFO Financial Highlights】**
- **2024 Revenue**: $4M from BARDA contract (vs. $0 in 2023), with potential to scale to $45M.
- **R&D Expenses**: $23.7M (14% YoY increase), driven by clinical trial manufacturing and vaccine development.
- **Net Loss**: $25M (vs. $26M in 2023), with $5.5M cash balance and active funding strategies to extend runway.

**【Q&A Key Takeaways】**
- **Mpox Emergency Use**: Exploring WHO emergency use pathways for GEO-MVA, with Africa CDC requesting 20M+ doses.
- **Gedeptin Trial Delay**: Phase 2 trial now expected mid-2026 due to manufacturing challenges.
- **BARDA Support Stability**: Weekly updates confirm no delays; HHS highlights vaccine's variant breadth and durability advantages over mRNA.
- **Clinical Trial Design**: GEO-CM04S1 trials focus on immunological endpoints, with 400+ subjects planned for Mpox vaccine trials.


GeoVax Labs (GOVX)-27 Mar 25-2024 Q4 Earnings call transcript

GeoVax Labs (GOVX)-12 Nov 24-2024 Q3 Earnings call transcript

Geovax Labs (GOVX)-6 Aug 24-2024 Q2 Earnings call transcript

Geovax Labs (GOVX)-14 May 24-2024 Q1 Earnings call transcript

- **Clinical Progress**: Gedeptin Phase II trial on track for Q1 2024 completion; GEO-CM04S1 targeting 15M immunocompromised patients globally. 
- **Financial Focus**: $18M net loss in Q3 driven by clinical trial costs; $12.7M cash balance. 
- **Strategic Momentum**: Project NextGen discussions could provide non-dilutive funding; MVA manufacturing platform enables rapid vaccine production. 
- **Market Differentiation**: GEO-CM04S1's dual-antigen approach offers superior durability to mRNA vaccines; Gedeptin addresses unmet need in head and neck cancer. 
- **Partnership Potential**: Actively engaging with global partners for worldwide commercialization of MVA-based vaccines.

**【CEO Summary Section】**
- GeoVax advanced two key products: Gedeptin (cancer therapy) and GEO-CM04S1 (next-gen COVID-19 vaccine). 
- Gedeptin targets advanced head and neck cancer patients (15,000 in the U.S., 400,000 globally) with unmet needs. Phase I data showed safety and tumor reduction; Phase II trial expected to complete Q1 2024.
- GEO-CM04S1 addresses immunocompromised populations (15M U.S., 240M global) where current vaccines fail. It uses a novel dual-antigen approach for broader, durable immunity.
- Project NextGen: GeoVax in active discussions for $5B U.S. initiative to fund next-gen COVID vaccines. $1.9B awarded so far, $3.1B remaining.
- Strategy: Innovate (MVA platform), Differentiate (tumor-agnostic Gedeptin), Accelerate (expedited trials), Collaborate (global partnerships).

**【CFO Financial Commentary】**
- Q3 2023: Net loss $18M ($0.69/share) vs $8.6M ($0.63/share) in 2022. 
- R&D expenses up 147% ($6.9M vs $2.7M) due to clinical trials and manufacturing costs. 
- G&A expenses up 35% ($1.7M vs $1.2M) from hiring and investor relations. 
- Cash balance $12.7M (down from $27.6M in 2022) due to operating expenses. 
- 2024 outlook: Continue funding Phase II trials; seek Project NextGen funding to reduce dilution.

**【Q&A Highlights】**
- **Paxlovid Impact**: No effect on GeoVax's target market. Immunocompromised patients still need better vaccines than monoclonal antibodies. 
- **Vaccine Differentiation**: GEO-CM04S1's dual-antigen approach offers broader protection than mRNA vaccines, potentially reducing booster frequency. 
- **Market Opportunity**: mRNA fatigue may drive demand for alternative vaccines with better safety profiles and durability.

GOVX

GOVX fundamentals

Earnings Call

You can ask Aime